Chemotherapy has relatively poor curative efficacy in<unk> C patients and overall survival rates are lower compared to patients with more typical cancer pathology.<unk> C cancers are usually diagnosed during the late stages of the disease, so the tumors generally spread more aggressively than non-signet cancers, making treatment challenging. In the future, case studies indicate that bone marrow metastases will likely play a larger role in the diagnosis and management of<unk> net<unk>  cell gastric cancer. In<unk> C of the stomach, removal of the stomach cancer is the treatment of choice. There is no combination of chemotherapy which is clearly superior to others, but most active regimens include 5-Fluorouracil (5-FU), Cisplatin, and/or Etoposide. Some newer agents, including Taxol and Gemcitabine (Gemzar) are under investigation. In a single case study of a patient with<unk> C of the bladder with recurrent metastases, the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy. There are reports of occasional pulmonary tumour thrombotic microangiopathy leading to pulmonary hypertension and coagulation problems that could be successfully treated with Imatinib.
Signet ring cell carcinoma
Adenomatoid tumor
Spindle cell carcinoma
Mucinous carcinoma
Mucoepidermoid carcinoma
Gastrointestinal stromal tumor
Mycetoma
Adenosarcoma